Citations

Showing 10 of 108104 citations.

The National Cancer Institute Cohort Consortium: An International Pooling Collaboration of 58 Cohorts from 20 Countries
Swerdlow, Anthony J. , Harvey, Chinonye E., Milne, Roger L. , Pottinger, Camille A. , Vachon, Celine M. , Gapstur, Susan M. , Weiderpass, Elisabete , Winn, Deborah M. , Weiderpass, Elisabete , Swerdlow, Anthony J , Milne, Roger L , Vachon, Celine M. , Wilkens, Lynne R. , Johansson, Mattias

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | July 17, 2018 | Volume: 27 | Issue: 11 | Pages: 1307-1319

10.1158/1055-9965.epi-18-0182 | PMID 30018149 Get It

Abstract Cohort studies have been central to the establishment of the known causes of cancer. To dissect cancer etiology in more detail—for instance, for personalized risk prediction and prevention, assessment of risks of subtypes of cancer, and assessment of small elevations in risk—there is a need for analyses of far larger cohort datasets than available in individual existing studies. To address these challenges, the NCI Cohort Consortium was founded in 2001. It brings together 58 cancer epidemiology cohorts from 20 countries to undertake large-scale pooling research. The cohorts in aggregate include over nine million study participants, with biospecimens available for about two million of these. Research in the Consortium is undertaken by >40 working groups focused on specific cancer sites, exposures, or other research areas. More than 180 publications have resulted from the Consortium, mainly on genetic and other cancer epidemiology, with high citation rates. This article describes the foundation of the Consortium; its structure, governance, and methods of working; the participating cohorts; publications; and opportunities. The Consortium welcomes new members with cancer-oriented cohorts of 10,000 or more participants and an interest in collaborative research. Cancer Epidemiol Biomarkers Prev; 27(11); 1307–19. ©2018 AACR.
Frequency of in‐hospital adverse outcomes and cost utilization associated with cardiac resynchronization therapy defibrillator implantation in the United States
Patel, Nilay , Viles-González, Juan F., Agnihotri, Kanishk, Arora, Shilpkumar , Patel, Nileshkumar , Aneja, Ekta, Shah, Mahek , Badheka, Apurva O., Pothineni, Naga Venkata K. , Kancharla, Krishna , Mulpuru, Siva K. , Cha, Yong‐Mei , Deshmukh, Abhishek , Pothineni, Naga Venkata , Mulpuru, Siva, Cha, Yong-Mei , Noseworthy, Peter A. , Kusumoto, Fred

Mayo Clinic

Journal of Cardiovascular Electrophysiology | July 17, 2018 | Volume: 29 | Issue: 10 | Pages: 1425-1435

10.1111/jce.13701 | PMID 30016005 Get It

AbstractBackground: The utilization of cardiac resynchronization therapy defibrillator (CRT‐D) has increased significantly, since its initial approval for use in selected patients with heart failure. Limited data exist as for current trends in implant‐related in‐hospital complications and cost utilization. The aim of our study was to examine in‐hospital complication rates associated with CRT‐D and their trends over the last decade.Methods and Results: Using the Nationwide Inpatient Sample, we estimated 378 248 CRT‐D procedures from 2003 to 2012. We investigated common complications, including mechanical, cardiovascular, pericardial complications (hemopericardium, cardiac tamponade, or pericardiocentesis), pneumothorax, stroke, vascular complications (consisting of hemorrhage/hematoma, incidents requiring surgical repair, and accidental arterial puncture), and in‐hospital deaths described with CRT‐D, defining them by the validated International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis code. Mechanical complications (5.9%) were the commonest, followed by cardiovascular (3.6%), respiratory failure (2.4%), and pneumothorax (1.5%). Age (≥65 years), female gender (OR, 95% CI; P value) (1.08, 1.03‐1.13; 0.001), and the Charlson score ≥3 (1.52, 1.45‐1.60; <0.001) were significantly associated with increased mortality/complications.Conclusions: The overall complication rate in patients undergoing CRT‐D has been increasing in the last decade. Age (≥65), female sex, and the Charlson score ≥3 were associated with higher complications. In patients who underwent CRT‐D implantation, postoperative complications were associated with significant increases in cost.
Radiation Dose in CT–guided Interventional Procedures: Establishing a Benchmark
Leng, Shuai , Leng, Shuai

Mayo Clinic

Radiology | July 17, 2018 | Volume: 289 | Issue: 1 | Pages: 158-159

10.1148/radiol.2018181245 | PMID 30015581 Get It

The Utility of MR Elastography to Differentiate Nodular Regenerative Hyperplasia from Cirrhosis
Navin, Patrick J. , Hilscher, Moira , Welle, Christopher L. , Mounajjed, Taofic, Kamath, Patrick S. , Venkatesh, Sudhakar K. , Hilscher, Moira B, Venkatesh, Sudhakar K , Navin, Patrick , Torbenson, Michael

Mayo Clinic

Hepatology | July 17, 2018 | Volume: 69 | Issue: 1 | Pages: 452-454

10.1002/hep.30175 | PMID 30014488 Get It

Effect ofBDNFVal66Met on disease markers in dominantly inherited Alzheimer's disease
Lim, Yen Ying , Hassenstab, Jason , Goate, Alison , Fagan, Anne M. , Benzinger, Tammie L.S. , Cruchaga, Carlos , Chhatwal, Jasmeer P. , Xiong, Chengjie , Farlow, Martin R. , Graff‐Radford, Neill R. , Laske, Christoph , Masters, Colin L. , Salloway, Stephen , Morris, John C. , Maruff, Paul , Bateman, Randall J. , Network, on behalf of the Dominantly Inherited Alzheimer, Cruchaga, Carlos , Bateman, Randall J , Masters, Colin L , Xiong, Chengjie , Benzinger, Tammie L S , Hassenstab, Jason , Morris, John C , McDade, Eric , Schofield, Peter R. , Network, on behalf of the Dominantly Inherited Alzheimer, Goate, Alison M , Maruff, Paul

Mayo Clinic

Annals of Neurology | July 17, 2018 | Volume: 84 | Issue: 3 | Pages: 424-435

10.1002/ana.25299 | PMID 30014553 Get It

ObjectivePrevious studies suggest that the brain‐derived neurotrophic factor (BDNF) Val66Met (rs6265) polymorphism may influence symptom onset in Alzheimer's disease (AD). Our recent cross‐sectional findings suggest that Met66 may influence clinical expression in dominantly inherited AD (DIAD) through its effects on tau. However, it remains unclear whether carriage of Met66 in DIAD results in faster increases in cerebrospinal fluid (CSF) tau and ptau181, and whether these increases are associated with accelerated brain volume loss and memory decline.MethodsA total of 211 subjects (101 mutation noncarriers, 110 mutation carriers), who were cognitively normal, as defined by a Clinical Dementia Rating global score of 0, completed assessments of cognitive function, neuroimaging, and CSF sampling over 3.5 years as part of the Dominantly Inherited Alzheimer's Network.ResultsIn mutation carriers, Met66 carriers showed faster memory decline (4×), hippocampal volume loss (16×), and CSF tau and ptau181increases (6×) than Val66 homozygotes.BDNFdid not influence rates of cortical β‐amyloid accumulation or change in CSF Aβ42levels in mutation carriers. In mutation noncarriers,BDNFgenotype had no effect on change in cognition, brain volume, cortical β‐amyloid accumulation, or change in any CSF measures of tau, ptau181, and CSF Aβ42.InterpretationAs in sporadic AD, the deleterious effects of β‐amyloid on cognitive function, brain volume loss, and CSF tau in DIAD mutation carriers are less in Val66 homozygotes. TheBDNFVal66Met polymorphism should be considered as a potential moderator of clinical trial outcomes in current treatment and prevention trials in DIAD and sporadic AD. Ann Neurol 2018;84:424–435
Identifying a newly discovered HLA‐C allele, HLA‐C*02:138
Knauer, R. , Dukek, Brian A. , Kubat, Doris, Kreuter, Justin D. , Knauer, R , Gandhi, Manish J.

Mayo Clinic

HLA | July 17, 2018 | Volume: 92 | Issue: 4 | Pages: 253-254

10.1111/tan.13341 | PMID 30014581 Get It

A new allele, now named HLA‐C*02:138, was discovered during testing of a registry donor for possible stem cell transplantation.
Teaching NeuroImages: Spinal cord syrinx secondary to a spinal dural arteriovenous fistula
Zaed, Ismail , Pinto, Marcus Vinícius , Mauermann, Michelle L. , Pinto, Marcus V, Pinto, Marcus V , Mauermann, Michelle L , Lanzino, Giuseppe

Mayo Clinic

Neurology | July 17, 2018 | Volume: 91 | Issue: 3 | Pages: No page available

10.1212/wnl.0000000000005830 | PMID 30012661 Get It

MULTIMODAL IMAGING OF MACULAR CHOROIDAL MACROVESSEL: A REPORT OF TWO CASES
Pennington, Justin D., Mashayekhi, Arman , Dalvin, Lauren A. , Shields, Carol L.

Mayo Clinic

RETINAL Cases & Brief Reports | July 16, 2018 | Volume: 15 | Issue: 3 | Pages: 218-223

10.1097/icb.0000000000000776 | PMID 30015777 Get It

Purpose: To report two cases of macular choroidal macrovessel with description of multimodal imaging and review of published cases. Methods: Medical and imaging records were retrospectively reviewed. A literature review was performed to identify other cases of macular choroidal macrovessel published between 1990 and 2018. Results: There were 2 patients referred for evaluation of a potential choroidal tumor, including a 55-year-old white woman with no visual symptoms and a 68-year-old white woman with blurred vision. Funduscopic examination in each case revealed a focal area of choroidal elevation in the temporal foveal area with a single, dilated, slightly tortuous choroidal vessel, estimated to measure 250 μm and 300 μm, respectively, at widest girth, and extending temporally toward the equator with a tapering width. Optical coherence tomography showed an optically hollow choroidal lesion elevating the retinal pigment epithelium with overlying ellipsoid zone mottling. Both cases demonstrate shallow subretinal fluid, sparing the foveola. Fluorescein angiography showed faint staining along the course of the vessel in both cases. Indocyanine green angiography demonstrated clear visualization of the ectatic vessel with early filling and late staining without leakage. Both patients retained visual acuity of 20/25 in the affected eye and did not require treatment. Conclusion: Macular choroidal macrovessel is a rare vascular anomaly presenting as a single, dilated, tortuous choroidal vessel, originating in the temporal foveal region and extending temporally to the equator. This finding can simulate a choroidal neoplasm or parasitic track. Optical coherence tomography and indocyanine green angiography have diagnostic value demonstrating the vascular nature of this lesion and delineating the vascular course.
Comparison of Pediatric Intercalary Allograft Reconstructions with and without a Free Vascularized Fibula
Rose, Peter S. , Milbrandt, Todd A. , Stans, Anthony A. , Moran, Steven L. , Sim, Franklin H. , Houdek, Matthew T.

Mayo Clinic

Plastic & Reconstructive Surgery | July 16, 2018 | Volume: 142 | Issue: 4 | Pages: 1065-1071

10.1097/prs.0000000000004794 | PMID 30020231 Get It

Background: Lower extremity intercalary allograft reconstruction has traditionally been used to facilitate limb salvage. Combining the allograft with a free vascularized fibula graft has been described; however, there is a paucity of data comparing the outcome of these reconstructions. Methods: Twenty-nine pediatric patients (15 boys and 14 girls) underwent lower extremity limb salvage with the use of intercalary cadaveric allograft at a mean age of 12 years. The most common diagnosis was osteosarcoma (n = 18). Patients underwent reconstruction with an allograft alone (n = 11) or supplemented with a free vascularized fibula graft (n = 18). Results: The mean time to union of the allograft was 11 months, with 10 patients requiring additional bone grafting. There was no difference in the need for an additional bone graft (OR, 0.87; p = 1.0) between patients with a free vascularized fibula graft and those without. The allograft was revised in three patients because of fracture (n = 2) and fracture and infection (n = 1). In all of these patients, the allograft was not supplemented with a free vascularized fibula graft (p < 0.001). Five patients underwent an amputation, most commonly for disease recurrence. At last follow-up, the mean Mankin and Musculoskeletal Tumor Society rating was 90 percent, with 19 patients (66 percent) who achieved a “good” or “excellent” outcome according to the Mankin score. Conclusion: Use of an intercalary allograft to reconstruct a lower extremity provides a durable means of reconstruction; however, supplementation with a free vascularized fibula graft reduces the risk of allograft revision. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.
Review: In type 2 diabetes, SGLT-2 inhibitors or GLP-1 agonists reduce mortality vs control or DPP-4 inhibitors
Egan, Aoife M. , Egan, A M , Montori, Víctor M.

Mayo Clinic

Annals of Internal Medicine | July 16, 2018 | Volume: 169 | Issue: 2 | Pages: JC2

10.7326/acpjc-2018-169-2-002 | PMID 30014091 Get It